Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/24/2003WO2003106394A1 Preparations containing conjugated linoleic alcohol
12/24/2003WO2003106385A2 Process for screening fungitoxic compounds
12/24/2003WO2003106381A2 Human adam-10 inhibitors
12/24/2003WO2003106380A2 Fluorobenzamides
12/24/2003WO2003105923A2 Use of y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation
12/24/2003WO2003105909A1 Medicine for prevention of and/or treatment for liver inshemiareperfusion injury and protective agent for transplant liver
12/24/2003WO2003105907A2 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
12/24/2003WO2003105906A1 A process for the preparation of piroxicam: b-cyclodextrin inclusion compounds
12/24/2003WO2003105905A1 Controlled release composition comprising felodipine and method of preparation thereof
12/24/2003WO2003105903A1 Antifungal medicinal composition
12/24/2003WO2003105902A1 Treatment for depression and anxiety by the combination of a pde iv inhibitor and an antidepressant or an anxiolytic agent
12/24/2003WO2003105901A2 New medical indication
12/24/2003WO2003105900A1 Regulation of secretory phospholipase a2 group iia
12/24/2003WO2003105896A1 Combined use of a modulator of cd3 and a beta cell resting compound
12/24/2003WO2003105882A1 Composition comprising viscous fibers and viscosity-lowering proteins
12/24/2003WO2003105881A1 Use of amide derivative of ge 2270 factor a3 for the treatment of acne
12/24/2003WO2003105879A1 Compositions and methods for preventing, treating and diagnosing diabetes
12/24/2003WO2003105878A1 Antibacterial agent and antibacterial composition
12/24/2003WO2003105870A1 Verotoxin production inhibitor
12/24/2003WO2003105869A1 Inhibitor of anticancer drug side effect
12/24/2003WO2003105868A1 Novel maxi-k channel blockers, methods of use and process for making the same
12/24/2003WO2003105867A1 Quaternised ammonium cyclodextrin compounds
12/24/2003WO2003105866A1 Products useful in the treatment of mmr deficient tumours
12/24/2003WO2003105865A1 Use of an anti-endotoxin drug in the prevention and treatment of disease
12/24/2003WO2003105864A1 Methods and compositions involving aldose reductase inhibitors
12/24/2003WO2003105863A1 Aryl phosphate derivatives with selective activity against adenovirus and hiv
12/24/2003WO2003105862A1 In-vivo energy depleting strategies for killing drug-resistant cancer cells
12/24/2003WO2003105861A1 Use of an anti-endotoxin drug in the prevention and treatment of disease
12/24/2003WO2003105860A1 Pharmaceutical use of boronic acids and esters thereof
12/24/2003WO2003105859A1 Powdery respiratory tonic composition
12/24/2003WO2003105858A1 Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
12/24/2003WO2003105857A1 Anti-inflammatory compositions and methods of use
12/24/2003WO2003105856A1 Combination of azelastine and steroids
12/24/2003WO2003105855A1 Mitotic kinesin inhibitors
12/24/2003WO2003105852A1 Use of dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation
12/24/2003WO2003105851A1 Novel crystalline forms of gatifloxacin
12/24/2003WO2003105849A1 Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
12/24/2003WO2003105848A1 Controlled-release drug composition
12/24/2003WO2003105847A1 Ophthalmic compositions for treating ocular hypertension
12/24/2003WO2003105844A1 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions
12/24/2003WO2003105843A1 Methods of using isothiazole derivatives to treat cancer or inflammation
12/24/2003WO2003105842A1 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
12/24/2003WO2003105841A1 Antifungal medicinal compositions
12/24/2003WO2003105840A2 Sphingosine kinase inhibitors
12/24/2003WO2003105839A1 Use of ribavirin for producing a pharmaceutical composition directed against bunyaviridae
12/24/2003WO2003105838A2 Metabolite
12/24/2003WO2003105837A1 Calcium salts of indole derived statins
12/24/2003WO2003105835A1 Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents
12/24/2003WO2003105834A1 Bazedoxifene treatment regimens
12/24/2003WO2003105833A1 Formulation of nefopam and its use in the treatment of pain
12/24/2003WO2003105832A1 Use of nefopam for the treatment of nausea or emesis
12/24/2003WO2003105831A1 Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
12/24/2003WO2003105830A1 Medicinal compositions improving brain function and method for improving brain function
12/24/2003WO2003105829A1 A formulation of traditional chinese medicine for preventing and treating osteoporosis
12/24/2003WO2003105828A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
12/24/2003WO2003105827A1 Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
12/24/2003WO2003105826A2 "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors."
12/24/2003WO2003105825A1 Use of hydroxyeicosatetraenoic acid compounds to treat vaginal dryness
12/24/2003WO2003105824A1 Topical use of hydroxyeicosatetraenoic acid compounds to treat psoriasis
12/24/2003WO2003105823A1 Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth
12/24/2003WO2003105822A1 Long chain unsaturated oxygenated compounds and their use in the therapeutical, cosmetic and nutraceutical field
12/24/2003WO2003105821A1 A pharmaceutical composition comprising a corticosteroid and a nonsterodial anti-inflammatory agent
12/24/2003WO2003105820A1 Inhibiting progressive cognitive impairment
12/24/2003WO2003105819A1 Quinone-type remedy for liver disease
12/24/2003WO2003105818A1 Quinone-based remedies for liver diseases
12/24/2003WO2003105817A1 Novel parenteral composition comprising propofol
12/24/2003WO2003105816A1 Method of treating rosacea by topical application of a cyclohexane derivative
12/24/2003WO2003105815A1 Combination of pde-v inhibitors and nk1 antagonists for the treatment of depression
12/24/2003WO2003105811A2 Controlled release compositions and methods for using same
12/24/2003WO2003105810A1 Pharmaceutical compositions for drugs having ph-dependentsolubility
12/24/2003WO2003105808A1 Abuse-protected administration form
12/24/2003WO2003105807A1 Microcrystalline zeaxanthin with high bioavailability in oily carrier formulations
12/24/2003WO2003105806A1 Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
12/24/2003WO2003105805A1 Composition for treatment of inflammatory disorders
12/24/2003WO2003105804A1 Ibuprofen suspension
12/24/2003WO2003105801A1 Cosmetic composition structured with silicone polymers and film-forming resins
12/24/2003WO2003105800A2 Film-shaped mucoadhesive administration form for administering cannabis active ingredients
12/24/2003WO2003105791A1 Use of astaxanthin
12/24/2003WO2003105781A2 Ophthalmic compositions for treating ocular hypertension
12/24/2003WO2003105780A2 A dry powder oligonucleotide formulation, preparation and its uses
12/24/2003WO2003105779A2 Guanidine compounds as anesthetics and for treatment of nervous system disorders
12/24/2003WO2003105776A2 ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
12/24/2003WO2003105775A2 Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
12/24/2003WO2003105774A2 Compounds useful for the treatment of cancer, compositions thereof and methods therewith
12/24/2003WO2003105771A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
12/24/2003WO2003105770A2 Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
12/24/2003WO2003105769A2 Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
12/24/2003WO2003105761A2 Immunotoxin as a therapeutic agent and uses thereof
12/24/2003WO2003105759A2 Pharmacologic inhibition of myc function
12/24/2003WO2003105752A2 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate)
12/24/2003WO2003105731A1 Bone growth compositions and methods
12/24/2003WO2003105724A2 Novel maxi-k channel blockers, methods of use and process for making the same
12/24/2003WO2003105666A2 Method of treating ischemia reperfusion injury using adenosine receptor antagonists
12/24/2003WO2003105609A1 Infant formula supplemented with phospholipids
12/24/2003WO2003105583A2 Antimicrobial and antiviral compositions containing an oxidizing species
12/24/2003WO2003096992A3 Treatment of cancer with mefloquire
12/24/2003WO2003096975A3 Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives
12/24/2003WO2003095455A3 Substituted pyrazolopyrimidines
12/24/2003WO2003091675A3 Ultrasonic doppler effect speed measurement
12/24/2003WO2003091232A3 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
1 ... 5233 5234 5235 5236 5237 5238 5239 5240 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 5252 5253 ... 7860